Fast Five Quiz: ERBB2 (HER2) Mutation in Non-Small Cell Lung Cancer

Maurie Markman, MD

Disclosures

November 23, 2021

Updated guidelines from the National Comprehensive Cancer Network list HER2 mutations as an emerging biomarker for targeted therapy with antibody drug conjugates (specifically, ado-trastuzumab emtansine and fam-trastuzumab deruxtecan-nxki). Access the full guidelines here.

Learn more about NSCLC treatment.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as:

processing....